Cas:151096-09-2 Moxifloxacin manufacturer & supplier

Chemical Name:Moxifloxacin

CAS.NO:151096-09-2

Synonyms:1-Cyclopropyl-6-fluoro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid;1-Cyclopropyl-6-fluoro-8-methoxy-7-((4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic Acid;MAXIOFFOXACIN;BAY 12-8039;1-cyclopropyl-6-fluoro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid;Moxifloxacin;Moxeza;Avdox;Vigamox;Avelox;3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-;Avalox;MFCD04117996

Molecular Formula:C₂₁H₂₄FN₃O₄

Molecular Weight:401.43

HS Code:29329970

Physical and Chemical Properties:

Melting point:193-195 °C(lit.)

Boiling point:636.4±55.0 °C at 760 mmHg

Density:1.4±0.1 g/cm3

Index of Refraction:1.633

PSA:83.80000

Exact Mass:

LogP:1.60

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 1-Cyclopropyl-6-fluoro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,MFCD04117996 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Moxeza Use and application,3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo- technical grade,usp/ep/jp grade.

Related News: AZ’s chief financial officer and incoming Alexion head Marc Dunoyer acknowledged that the reimbursement infrastructure for rare disease drugs in China isn’t as advanced as it is in many developed economies. The rare disease market in China is still small, but there’s a growing recognition of its importance from authorities, he added. [(2R,3S,5R)-5-(6-aminopurin-9-yl)-2-(phosphonooxymethyl)oxolan-3-yl] [(2R,3S,5R)-5-(2,4-dioxopyrimidin-1-yl)-3-hydroxyoxolan-2-yl]methyl hydrogen phosphate manufacturers The company pinpointed Thousand Oaks for its expansion “based on capability, staffing as well as the local community and the things we could bring to the area,” Hatke, told the news outlet. 5-Methansulfonyloxy-1-indanon suppliers In SLE, along with the pivotal TULIP phase III programme, anifrolumab continues to be evaluated in a long-term extension phase III trial.12 A phase II trial of anifrolumab in SLE using subcutaneous delivery has been completed. (R)-2,5,7,8-tetramethylchromane-2-carboxylic acid vendor & factory.